Clinical Scorecard: Optimizing Polycythemia Vera Management Through a Collaborative Care Model Between Leukemia Oncologists and an Integrated Specialty Pharmacy

At a Glance

Key Highlights

• Optimal care can lead to a normal lifespan for many PV patients.
• Management strategies focus on minimizing thrombotic and hemorrhagic complications.
• Pharmacists play a crucial role in bridging care gaps and optimizing treatment.
• The MPN-10 tool is recommended for assessing symptom burden but is underutilized.
• A pharmacist-led program significantly improved hematocrit control in PV patients.

Guideline-Based Recommendations

Diagnosis

• Diagnosis based on clinical presentation and JAK2 mutation testing.

Management

• Therapeutic phlebotomy and low-dose aspirin for low-risk patients.
• Cytoreductive therapy for high-risk or uncontrolled patients.

Monitoring & Follow-up

• Regular monitoring of hematocrit levels to achieve target < 45%.

Risks

• Increased thrombotic risk associated with elevated blood viscosity.

Patient & Prescribing Data

Patients with Polycythemia Vera, categorized as low or high risk.

Cytoreductive therapy options include hydroxyurea, interferons, or JAK inhibitors.

Clinical Best Practices

• Utilize the MPN-10 for symptom assessment at least quarterly.
• Implement a standardized, multidisciplinary approach to care.
• Engage pharmacists for medication management and adherence support.

Related Resources & Content

• Iurlo et al., 2020
• Tefferi et al., 2021
• Marchioli et al., 2011
• Gerds et al., 2022
• Marchetti et al., 2022
• Nurgat & Lawrence, 2022
• Ferrari et al., 2019
• Yacoub et al., 2019
• Andrick et al., 2020
• Chojecki et al., 2022